Refine
Has Fulltext
- yes (61)
Is part of the Bibliography
- yes (61) (remove)
Year of publication
Document Type
- Doctoral Thesis (61) (remove)
Language
- English (61) (remove)
Keywords
- Maus (61) (remove)
Institute
- Graduate School of Life Sciences (32)
- Theodor-Boveri-Institut für Biowissenschaften (13)
- Rudolf-Virchow-Zentrum (9)
- Institut für Medizinische Strahlenkunde und Zellforschung (4)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (4)
- Neurologische Klinik und Poliklinik (4)
- Institut für Virologie und Immunbiologie (3)
- Institut für Klinische Biochemie und Pathobiochemie (2)
- Lehrstuhl für Molekulare Psychiatrie (2)
- Medizinische Fakultät (2)
Sonstige beteiligte Institutionen
Aging is known to be a risk factor for structural abnormalities and functional decline in the nervous system. Characterizing age-related changes is important to identify putative pathways to overcome deleterious effects and improve life quality for the elderly. In this study, the peripheral nervous system of 24-month-old aged C57BL/6 mice has been investigated and compared to 12-month-old adult mice. Aged mice showed pathological alterations in their peripheral nerves similar to nerve biopsies from elderly human individuals, with nerve fibers showing demyelination and axonal damage. Such changes were lacking in nerves of adult 12-month-old mice and adult, non-aged humans. Moreover, neuromuscular junctions of 24-month-old mice showed increased denervation compared to adult mice. These alterations were accompanied by elevated numbers of macrophages in the peripheral nerves of aged mice. The neuroinflammatory conditions were associated with impaired myelin integrity and with a decline of nerve conduction properties and muscle strength in aged mice.
To determine the pathological impact of macrophages in the aging mice, macrophage depletion was performed in mice by oral administration of CSF-1R specific kinase (c-FMS) inhibitor PLX5622 (300 mg/kg body weight), which reduced the number of macrophages in the peripheral nerves by 70%. The treated mice showed attenuated demyelination, less muscle denervation and preserved muscle strength. This indicates that macrophage-driven inflammation in the peripheral nerves is partially responsible for the age-related neuropathy in mice.
Based on previous observations that systemic inflammation can accelerate disease progression in mouse models of neurodegenerative diseases, it was hypothesized that systemic inflammation can exacerbate the peripheral neuropathy found in aged mice. To investigate this hypothesis, aged C57BL/6 mice were intraperitoneally injected with a single dose of lipopolysaccharide (LPS; 500 μg/kg body weight) to induce systemic inflammation by mimicking bacterial infection, mostly via activation of Toll-like receptors (TLRs). Altered endoneurial macrophage activation, highlighted by Trem2 downregulation, was found in LPS injected aged mice one month after injection. This was accompanied by a so far rarely observed form of axonal perturbation, i.e., the occurrence of “dark axons” characterized by a damaged cytoskeleton and an increased overall electron density of the axoplasm. At the same time, however, LPS injection reduced demyelination and muscle denervation in aged mice. Interestingly, TREM2 deficiency in aged mice led to similar changes to LPS injection. This suggests that LPS injection likely mitigates aging-related demyelination and muscle denervation via Trem2 downregulation.
Taken together, this study reveals the role of macrophage-driven inflammation as a pathogenic mediator in age-related peripheral neuropathy, and that targeting macrophages might be an option to mitigate peripheral neuropathies in aging individuals. Furthermore, this study shows that systemic inflammation may be an ambivalent modifier of age-related nerve damage, leading to a distinct type of axonal perturbation, but in addition to functionally counteracting, dampened demyelination and muscle denervation. Translationally, it is plausible to assume that tipping the balance of macrophage polarization to one direction or the other may determine the functional outcome in the aging peripheral nervous system of the elderly.
The mammalian Vasodilator Stimulated Phosphoprotein (VASP) is a founding member of the Ena/VASP family of proteins that includes Drosophila Enabled (ena), the mammalian Ena homologue (Mena) and the Ena-VASP-like protein (Evl). VASP was initially discovered and characterized as a substrate for cGMP- and cAMP-dependent protein kinases (cGKs and cAKs). Ena/VASP proteins are involved in Actin-filament formation, plasma membrane protrusion, acceleration of Actin-based motility of Listeria and the establishment of cell-cell adhesion. Moreover, Ena/VASP proteins have been implicated as inhibitory factors in repulsive axon guidance and inhibition of plasma membrane activity and random motility in fibroblast. In order to study the physiological function of VASP, VASP-deficient mice had been generated in the laboratory by homologous recombination. VASP-/- mice showed hyperplasia of megakaryocytes in the bone marrow and spleen and a two-fold increase in thrombin- and collagen-induced platelet activation. To further investigate the cellular function of VASP, I established cardiac fibroblast cell lines derived from both wild type and VASP-/- mice. Both cell lines presented similar growth rates and normal contact dependent-growth inhibition but showed differences in morphology, migration and adhesion. Adherent VASP-/- cells, despite normal Mena and Evl expression levels, were highly spread. VASP-/- cells covered about twice the substrate surface area as wild type cells, while the cell volumes were unchanged. This shape difference suggests that VASP is involved in the regulation of spreading. Since the small GTPases Rac and Cdc 42 and their effector p21-activated kinase (Pak) are key regulators of lamellipodia formation and cell spreading, I analyzed this signalling pathway in VASP-/- cells stimulated with Platelet Derived Growth Factor-BB (PDGF-BB) or fetal calf serum. In wild type cells Rac and Pak were rapidly and transiently activated by PDGF or serum; however, in the absence of VASP both Rac and Pak activation was dramatically prolonged. The Rac/Pak pathway is known to play an essential role in cell motility. VASP deficient cells showed compromised migration and reorientation in a wound healing assay, probably due to enhanced Rac activity. The spreading phenotype, compromised migration and the effect observed on the Rac and Pak activities were reverted in VASP-/- cells stably transfected with full lenght human VASP, indicating a VASP dependent modulation of the Rac/Pak pathway and Rac/Pak regulated processes. Moreover, adhesion and detachment of VASP-deficient cells were significantly slower when compared to wild type cells. Preincubation of VASP+/+ cells with a cGMP analog accelerated adhesion. This acceleration did not take place in the VASP-/- cells, suggesting a VASP dependent effect. The second part of this work focused on VASP function in platelets. On the one hand I investigated the possibility of VASP-dependent Rac regulation in mouse platelets. Murine platelets are a good model for studying Rac regulation since they express high levels of VASP but not Mena/Evl and since VASP-deficient platelets show an increased platelet activation. Rac was activated by platelet agonists which was inhibited by preincubation with cGMP and cAMP analogs. Initial results which need to be extended showed that the cGMPcaused inhibition of Rac activation was VASP-dependent. Finally, in vivo platelet adhesion (platelet-vessel wall interactions) was studied using VASP-deficient mice. These studies demonstrated in-vivo that VASP down regulates platelet adhesion to the vascular wall under both physiological and pathophysiological conditions.
Atherosclerosis is accepted to be a chronic inflammatory disease of the arterial vessel wall. Several cellular subsets of the immune system are involved in its initiation and progression, such as monocytes, macrophages, T and B cells. Recent research has demonstrated that dendritic cells (DCs) contribute to atherosclerosis, too. DCs are defined by their ability to sense and phagocyte antigens, to migrate and to prime other immune cells, such as T cells. Although all DCs share these functional characteristics, they are heterogeneous with respect to phenotype and origin. Several markers have been used to describe DCs in different lymphoid and non-lymphoid organs; however, none of them has proven to be unambiguous. The expression of surface molecules is highly variable depending on the state of activation and the surrounding tissue. Furthermore, DCs in the aorta or the atherosclerotic plaque can be derived from designated precursor cells or from monocytes. In addition, DCs share both their marker expression and their functional characteristics with other myeloid cells like monocytes and macrophages. The repertoire of aortic DCs in healthy and atherosclerotic mice has just recently started to be explored, but yet there is no systemic study available, which describes the aortic DC compartment. Because it is conceivable that distinct aortic DC subsets exert dedicated functions, a detailed description of vascular DCs is required. The first part of this thesis characterizes DC subsets in healthy and atherosclerotic mice. It describes a previously unrecognized DC subset and also sheds light on the origin of vascular DCs. In recent years, microRNAs (miRNAs) have been demonstrated to regulate several cellular functions, such as apoptosis, differentiation, development or proliferation. Although several cell types have been characterized extensively with regard to the miRNAs involved in their regulation, only few studies are available that focus on the role of miRNAs in DCs. Because an improved understanding of the regulation of DC functions would allow for new therapeutic options, research on miRNAs in DCs is required. The second part of this thesis focuses on the role of the miRNA cluster miR- 17~92 in DCs by exploring its functions in healthy and atherosclerotic mice. This thesis clearly demonstrates for the first time an anti-inflammatory and atheroprotective role for the miR17-92 cluster. A model for its mechanism is suggested.
Platelet interaction with the subendothelium is essential to limit blood loss after tissue injury. However, upon rupture of atherosclerotic plaques, this interaction may result in blood vessel occlusion leading to life threatening diseases such as myocardial infarction or stroke. Among the subendothelial matrix proteins, collagen is considered to be the most thrombogenic component as it directly activates platelets. Platelets interact with collagen, either indirectly through glycoprotein (GP) Ib-V-IX receptor complex, or directly through the major collagen receptor on the platelet surface, GPVI. The work presented here focused on studying the cellular regulation of GPVI. In addition, a possible role for GPVI in thrombus formation induced by atherosclerotic plaque material was investigated and it was found that GPVI plays an important role in this process. Using a recently published mitochondrial injury model, it was found that GPVI contains a cleavage site for a platelet-expressed metalloproteinase. Further studies showed that platelet activation by CRP, or thrombin induced down-regulation of GPIb, but not GPVI. In parallel, cellular regulation of GPV was studied and it was found that GPV is cleaved in vitro by the metalloproteinase ADAM17. In previous studies it was shown that injection of mice with the anti-GPVI mAb, JAQ1, induces GPVI down-regulation, which is associated with a strong, but transient, thrombocytopenia. Using new anti-GPVI mAbs, which bind different epitopes on the receptor, it is shown in this study that GPVI down-regulation occurs in an epitope-independent manner. Further experiments showed that antibody treatment induces a transient, but significant increase in bleeding time. Using different genetically modified mice, it is shown that, upon antibody injection, GPVI is both, shed from the platelet surface and internalized into the platelet. Signaling through the immunoreceptor tyrosine-based activation motif (ITAM) of the FcR chain is essential for both processes, while LAT and PLC2 are essential for the shedding process only. Antibody-induced increase in bleeding time and thrombocytopenia were absent in LAT deficient mice, showing that it is possible to uncouple the associated side effects from the down-regulation process. As antibody-induced GPVI internalization still occurs in LAT and PLC2 deficient mice, this suggests a novel signaling pathway downstream of GPVI that has not been described so far.
Mammalian haloacid dehalogenase (HAD)-type phosphatases are a large and ubiquitous family of at least 40 human members. Many of them have important physiological functions, such as the regulation of intermediary metabolism and the modulation of enzyme activities, yet they are also linked to diseases such as cardiovascular or metabolic disorders and cancer.
Still, most of the mammalian HAD phosphatases remain functionally uncharacterized.
This thesis reveals novel cell biological and physiological functions of the phosphoglycolate phosphatase PGP, also referred to as AUM. To this end, PGP was functionally characterized by performing analyses using purified recombinant proteins to investigate potential protein substrates of PGP, cell biological studies using the spermatogonial cell line GC1, primary mouse lung endothelial cells and lymphocytes, and a range of biochemical techniques to characterize Pgp-deficient mouse embryos.
To characterize the cell biological functions of PGP, its role downstream of RTK- and integrin signaling in the regulation of cell migration was investigated. It was shown that PGP inactivation elevates integrin- and RTK-induced circular dorsal ruffle (CDR) formation, cell spreading and cell migration. Furthermore, PGP was identified as a negative regulator of directed lymphocyte migration upon integrin- and GPCR activation.
The underlying mechanisms were analyzed further. It was demonstrated that PGP regulates CDR formation and cell migration in a PLC- and PKC-dependent manner, and that Src family kinase activities are required for the observed cellular effects. Upon integrin- and RTK activation, phosphorylation levels of tyrosine residues 1068 and 1173 of the EGF receptor were elevated and PLCγ1 was hyper-activated in PGP-deficient cells. Additionally, PGP-inactivated lymphocytes displayed elevated PKC activity, and PKC-mediated cytoskeletal remodeling was accelerated upon loss of PGP activity. Untargeted lipidomic analyses revealed that the membrane lipid phosphatidylserine (PS) was highly upregulated in PGP-depleted cells.
These data are consistent with the hypothesis that the accumulation of PS in the plasma membrane leads to a pre-assembly of signaling molecules such as PLCγ1 or PKCs that couple the activation of integrins, EGF receptors and GPCRs to accelerated cytoskeletal remodeling.
Thus, this thesis shows that PGP can affect cell spreading and cell migration by acting as a PG-directed phosphatase.
To understand the physiological functions of PGP, conditionally PGP-inactivated mice were analyzed. Whole-body PGP inactivation led to an intrauterine growth defect with developmental delay after E8.5, resulting in a gradual deterioration and death of PgpDN/DN embryos between E9.5 and E11.5. However, embryonic lethality upon whole-body PGP inactivation was not caused by a primary defect of the (cardio-) vascular system. Rather, PGP inactivated embryos died during the intrauterine transition from hypoxic to normoxic conditions.
Therefore, the potential impact of oxygen on PGP-dependent cell proliferation was investigated. Analyses of mouse embryonic fibroblasts (MEFs) generated from E8.5 embryos and GC1 cells cultured under normoxic and hypoxic conditions revealed that normoxia (~20% O2) causes a proliferation defect in PGP-inactivated cells, which can be rescued under
hypoxic (~1% O2) conditions. Mechanistically, it was found that the activity of triosephosphate isomerase (TPI), an enzyme previously described to be inhibited by phosphoglycolate (PG) in vitro, was attenuated in PGP-inactivated cells and embryos. TPI constitutes a critical branch point between carbohydrate- and lipid metabolism because it catalyzes the isomerization of the glycolytic intermediates dihydroxyacetone phosphate (DHAP, a precursor of the glycerol backbone required for triglyceride biosynthesis) and glyceraldehyde 3’-phosphate (GADP).
Attenuation of TPI activity, likely explains the observed elevation of glycerol 3-phosphate levels and the increased TG biosynthesis (lipogenesis). Analyses of ATP levels and oxygen consumption rates (OCR) showed that mitochondrial respiration rates and ATP production were elevated in PGP-deficient cells in a lipolysis-dependent manner. However under hypoxic conditions (which corrected the impaired proliferation of PGP-inactivated cells), OCR and ATP production was indistinguishable between PGP-deficient and PGP-proficient cells. We therefore propose that the inhibition of TPI activity by PG accumulation due to loss of PGP activity shifts cellular bioenergetics from a pro-proliferative, glycolytic metabolism to a lipogenetic/lipolytic metabolism.
Taken together, PGP acts as a metabolic phosphatase involved in the regulation of cell migration, cell proliferation and cellular bioenergetics. This thesis constitutes the basis for further studies of the interfaces between these processes, and also suggests functions of PGP for glucose and lipid metabolism in the adult organism.
Optical in vivo imaging methods have advanced the fields of stem cell transplantation, graft-versus–host disease and graft-versus-tumor responses. Two well known optical methods, based on the transmission of light through the test animal are bioluminescence imaging (BLI) and fluorescence imaging (FLI). Both methods allow whole body in vivo imaging of the same animal over an extended time span where the cell distribution and proliferation can be visualized. BLI has the advantages of producing almost no unspecific background signals and no necessity for external excitation light. Hence, BLI is a highly sensitive and reliable detection method. Yet, the BLI reporter luciferase is not applicable with common microscopy techniques, therefore abolishing this method for cellular resolution imaging. FLI in turn, presents the appealing possibility to use one fluorescent reporter for whole body imaging as well as cellular resolution applying microscopy techniques. The absorption of light occurs mainly due to melanin and hemoglobin in wavelengths up to 650 nm. Therefore, the wavelength range beyond 650 nm may allow sensitive optical imaging even in deep tissues. For this reason, significant efforts are undertaken to isolate or develop genetically enhanced fluorescent proteins (FP) in this spectral range. “Katushka” also called FP635 has an emission close to this favorable spectrum and is reported as one of the brightest far-red FPs. Our experiments also clearly showed the superiority of BLI for whole body imaging over FLI. Based on these results we applied the superior BLI technique for the establishment of a pre-clinical multiple myeloma (MM) mouse model. MM is a B-cell disease, where malignant plasma cells clonally expand in the bone marrow (BM) of older people, causing significant morbidity and mortality. Chromosomal abnormalities, considered a hallmark of MM, are present in nearly all patients and may accumulate or change during disease progression. The diagnosis of MM is based on clinical symptoms, including the CRAB criteria: increased serum calcium levels, renal insufficiency, anemia, and bone lesions (osteolytic lesions or osteoporosis with compression fractures). Other clinical symptoms include hyperviscosity, amyloidosis, and recurrent bacterial infections. Additionally, patients commonly exhibit more than 30% clonal BM plasma cells and the presence of monoclonal protein is detected in serum and/or urine. With current standard therapies, MM remains incurable and patients diagnosed with MM between 2001 and 2007 had a 5-year relative survival rate of only 41%. Therefore, the development of new drugs or immune cell-based therapies is desirable and necessary. To this end we developed the MOPC-315 cell line based syngeneic MM mouse model. MOPC-315 cells were labeled with luciferase for in vivo detection by BLI. We validated the non-invasively obtained BLI data with histopathology, measurement of idiotype IgA serum levels and flow cytometry. All methods affirmed the reliability of the in vivo BLI data for this model. We found that this orthotopic MM model reflects several key features of the human disease. MOPC-315 cells homed efficiently to the BM compartment including subsequent proliferation. Additionally, cells disseminated to distant skeletal parts, leading to the typical multifocal MM growth. Osteolytic lesions and bone remodeling was also detected. We found evidence that the cell line had retained plasticity seen by dynamic receptor expression regulation in different compartments such as the BM and the spleen.
Prion diseases such as scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle or Creutzfeldt-Jakob disease (CJD) in humans are fatal neurodegenerative disorders characterized by brain lesions and the accumulation of a disease-associated protein, designated PrPSc. How prions proceed to damage neurons and whether all or only subsets of neurons have to be affected for the onset of the clinical disease is still elusive. The manifestation of clinical prion disease is characterized by motor dysfunctions, dementia and death. Furthermore loss of motor neurons (MN) in the spinal cord is a constant finding in different mouse models of prion disease, suggesting that MN are vulnerable cells for triggering the onset of clinical symptoms. To determine whether the protection of MN against prion induced dysfunctions is an approach for holding the disease at the sub-clinical level, we established a novel conditional model for Cre-mediated expression of a dominant-negative PrP mutant (PrPQ167R) in the cells of interest. Dominant-negative PrP mutants provide protection of prion induced dysfunctions by inhibiting prion replication. Transgenic mice were generated carrying a floxed LacZ marker gene followed by the coding sequence of PrPQ167R under control of the human ubiquitin C promoter. Two Cre strains have been used to direct PrPQ167R expression either to a subset of MN of the spinal cord (Hb9-Cre) or to various neuronal cell populations of the spinal cord and brain (NF-L-Cre). Transgenic mice were infected with mouse-adapted prions via different inoculation routes (intranerval, intracerebral and intraperitoneal) and monitored for effects on incubation time and pathology. Tg floxed LacZ-PrPQ167R/NF-L-Cre mice showed about 15% prolonged survival upon intraperitoneal low dose prion infection, whereas survival of Tg floxed LacZ-PrPQ167R/Hb9-Cre mice was comparable to control littermates. The results suggest that the protection of spinal MN prolongs the incubation period but is not sufficient to completely inhibit clinical prion disease. In a second approach, Cre was transferred into the hind limb muscles of transgenic mice via a double-stranded adeno-associated virus vector (dsAAV2-Cre). The goal of this strategy was to target a broader cell population and thus to enhance expression levels of protective PrPQ167R in the spinal cord of Tg floxed-LacZ-PrPQ167R mice. After intramuscular (i.m.) application of dsAAV2-Cre, exhibiting a physical titer of 5x1010 GP/ml, recombinant transgenic DNA was detected only in the muscle tissue, pointing out that functional Cre-recombinase was expressed at the side of virus application. However, dsAAV2-Cre did neither induce recombination of transgenic DNA in the spinal cord or brain nor expression of dominant-negative PrPQ167R. In conclusion the dsAAV2-Cre vectors system needs further improvement to achieve efficient transport from muscle tissue to the central nervous system (CNS). 105 7 SUMMARY The lymphoreticular system (LRS) is an early site of prion replication. In splenic tissue prion infectivity is associated with follicular dendritic cells (FDC) as well as with Band T-lymphocytes. However, it is still unknown if those cell types are able to replicate the infectious agent or if other PrP-expressing cell types are engaged. To investigate if neurons and in particular MN are involved, transgenic mice carrying one allele of floxed Prnp (lox2+=��) and either one allele of Hb9-Cre or NF-L-Cre were generated on a Prnp0=0 background. Therefore a conditional PrP knockout was established in a subset of MN of the spinal cord (Hb9-Cre) or in various neuronal populations of the spinal cord and brain (NF-L-Cre). Transgenic mice were inoculated with prions to study the accumulation of PrPSc and prion infectivity in spleen and spinal cord at an early time point after infection. The findings show that PrPSc accumulation in mice with MN-specific PrP depletion (lox2+=��/ Hb9-Cre) was comparable to control littermates, while pan-neuronal PrP deficient mice (lox2+=��/NF-L-Cre) were not able to accumulate PrPSc in splenic tissue until 50 days post inoculation. Moreover spleens of lox2+=��/NF-L-Cre mice exhibited a clearly reduced prion infectivity titer, suggesting that accumulation of prions in the spleen is dependent on PrP expression in the nervous tissue.
Stress has been shown to influence neuroplasticity and is suspected to increase the risk for psychiatric disorders such as major depression and anxiety disorders. Additionally, the short variant of the human serotonin transporter (5-HTT) length polymorphism (5-HTTLPR) is suggested to increase the risk for the development of such disorders. While stress as well as serotonergic signaling are not only discussed to be involved in the development of psychiatric disorders, they are also known to influence hippocampal adult neurogenesis (aN). Therefore, it has long been suspected that aN is involved in the etiology of these illnesses. The exact role of aN in this context however, still remains to be clarified.
In the present doctoral thesis, I am introducing two different studies, which had been carried out to assess possible changes in neuroplasticity and behavior as a result of 5-HTT genotype by stress interactions. In both studies, animals of the 5-HTT knock-out (5-HTT-/-) mouse line were used, which have been found to exhibit increased anxiety- and depression-related behavior, an altered stress response and decreased aggressive behavior. The aim of the first study, the so-called Spatial Learning study, had been to evaluate whether mice with altered levels of brain 5-HT as a consequence of lifelong 5-HTT deficiency perform differently in two spatial memory tests, the Morris Water Maze (WM) and the Barnes Maze (BM) test prospectively differing in aversiveness. Mice of the Spatial Learning study were of male sex and six months of age, and where subjected to a total of 10 (BM) or 15 (WM) trials. My particular interest was to elucidate if there are genotype by treatment interactions regarding blood plasma corticosterone levels and, if neurobiological equivalents in the brain to the found behavioral differences exist. For this purpose I carried out a quantitative immunohistochemistry study, investigating stem cell proliferation (via the marker Ki67) and aN (via the immature neuron marker NeuroD), as well as expression of the two immediate early genes (IEGs) Arc and cFos as a markers for neuronal activity in the hippocampus. The aim of the second study, the chronic mild stress (CMS) study had been to evaluate whether the innate divergent depression-like and anxiety-like behavior of mice with altered levels of brain 5-HT as a consequence of 5-HTT-deficiency is altered any further after being subjected to a CMS paradigm. Two cohorts of one-year-old female mice had been subjected to a variety of unpredictable stressors. In order to exclude possible interfering influences of behavioral testing on corticosterone levels and the outcome of the quantitative immunohistochemistry study the first cohort had been behaviorally tested after CMS while the second one had remained behaviorally untested. The objective of my part of the study was to find out about possible genotype by treatment interactions regarding blood plasma corticosterone as well as regarding aN in the hippocampus of the mice that had been subjected to CMS. For this purpose I performed a quantitative immunohistochemistry study in order to investigate the phenomenon of adult neurogenesis (via Ki67, NeuroD and the immature neuron marker DCX).
Both studies led to interesting results. In the CMS study, we could not replicate the increased innate anxiety- and depression-like behavior in 5-HTT-/- mice known from the literature. However, with regard to the also well documented reduced locomotor activity, as well as the increased body weight of 5-HTT-/- mice compared to their 5-HTT+/- and 5-HTT+/+ littermates, we could demonstrate that CMS leads to increased explorative behavior in the Open Field Test and the Light/Dark Box primarily in 5-HTT+/- und 5-HTT+/+ mice. The Spatial learning study revealed that increased stress sensitivity of 5-HTT-/- mice leads to a poorer performance in the WM test in relation to their 5-HTT+/+ and 5-HTT+/- littermates. As the performance of 5-HTT-/- mice in the less aversive BM was undistinguishable from both other genotypes, we concluded that the spatial learning ability of 5-HTT-/- mice is comparable to that of both other genotypes. As far as stress reactivity is concerned, the experience of a single trial of either the WM or the BM resulted in increased plasma corticosterone levels, irrespective of the 5-HTT genotype. After several trials 5-HTT-/- mice exhibited higher corticosterone concentrations compared with both other genotypes in both tests. Blood plasma corticosterone levels were highest in 5-HTT-/- mice tested in the WM indicating greater aversiveness of the WM and a greater stress sensitivity of 5-HTT deficient mice. In the CMS study, the corticosterone assessment of mice of cohort 1, which had undergone behavioral testing before sacrifice, resulted in significantly elevated corticosterone levels in 5-HTT-/- mice in relation to their 5-HTT+/+ controls. Contrary, corticosterone levels in mice of cohort 1, which had remained behaviorally untested, were shown to be elevated / increased after CMS experience regardless of the 5-HTT genotype. Regarding neuroplasticity, the Spatial Learning study revealed higher baseline levels of cFos- and Arc-ir cells as well as more proliferation (Ki67-ir cells) and higher numbers of neuronal progenitor cells (NeuroD-ir cells) in 5-HTT-/- compared to 5-HTT+/+ mice. Moreover, in 5-HTT-/- mice we could demonstrate that learning performance in the WM correlates with the extent of aN. The CMS study, in which aN (DCX-ir cells), has also been found to be increased in 5-HTT-/- mice compared to their 5-HTT+/+ littermates, yet only in control animals, did show hampered proliferation (Ki67-ir cells) in the hippocampus of all 5-HTT genotypes following CMS experience. Interestingly, the number of immature neurons (DCX-ir cells) was diminished exclusively in 5-HTT-/- mice in response to CMS.
From the Spatial Learning study we concluded, that increased IEG expression and aN levels observed in the hippocampus of 5-HTT deficient mice can be the neurobiological correlate of emotion circuit dysfunction and heightened anxiety of these mice and that 5-HTT-/- animals per se display a “stressed” phenotype as a consequence of long-life 5-HTT deficiency. Due to the different age and sex of the mice in the two studies, they cannot be compared easily. However, although the results of the CMS study seem to contradict the results of the Spatial Learning study at the first glance, they do support the conclusion of the Spatial Learning study by demonstrating that although CMS does have an impact on 5-HTT-/- mice on the neurobiological level (e.g. manifesting in a decrease of DXC-ir cells following CMS) CMS experience cannot add onto their heightened inborn stress-level and is almost ineffective regarding further changes of the behavior of 5-HTT-deficient mice. I thus propose, that 5-HTT-/- mice as a result of lifelong altered 5-HT signaling display a stressed phenotype which resembles a state of lethargy and is paralleled by baseline heightened IEG expression and aN. It cannot be altered or increased by CMS, but it becomes most visible in stressful situations such as repeated spatial learning tests like the WM in which locomotor activity is required.
Hematopoietic stem cell transplantation is a curative therapy for malignant diseases of the haematopoietic system. The patients first undergo chemotherapy or irradiation therapy which depletes the majority of tumour cells before they receive the transplant, consisting of haematopoietic stem cells and mature T cells from a healthy donor. The donor T cells kill malignant cells that have not been eliminated by the conditioning therapy (graft versus leukaemia effect, GvL), and, therefore, are crucially required to prevent relapse of the tumour. However, the donor T cells may also severely damage the patient’s organs causing acute graft versus host disease (aGvHD). In mice, aGvHD can be prevented by interfering with the co-stimulatory CD28 signal on donor T cells. However, experimental models using conventional CD28 knockout mice as T cell donors or αCD28 antibodies have some disadvantages, i.e. impaired T cell development in the thymus of CD28 knockout mice and systemic CD28 blockade with αCD28 antibodies. Thus, it remains unclear how CD28 co-stimulation on different donor T cell subsets contributes to the GvL effect and aGvHD, respectively.
We developed mouse models of aGvHD and the GvL effect that allowed to selectively delete CD28 on certain donor T cell populations or on all donor T cells. CD4+ conventional T cells (Tconv cells), regulatory T cells (Treg cells) or CD8+ T cells were isolated from either Tamoxifen-inducible CD28 knockout (iCD28KO) mice or their wild type (wt) littermates. Allogeneic recipient mice were then transplanted with T cell depleted bone marrow cells and different combinations of iCD28KO and wt T cell subsets. Tamoxifen treatment of the recipients caused irreversible CD28 deletion on the iCD28KO donor T cell population. In order to study the GvL response, BCL-1 tumour cells were injected into the mice shortly before transfer of the T cells.
CD4+ Tconv mediated aGvHD was efficiently inhibited when wt Treg cells were co-transplanted. In contrast, after selective CD28 deletion on donor Treg cells, the mice developed a late and lethal flare of aGvHD, i.e. late-onset aGvHD. This was associated with a decline in iCD28KO Treg cell numbers around day 20 after transplantation. CD28 ablation on either donor CD4+ Tconv cells or CD8+ T cells reduced but did not abrogate aGvHD. Moreover, iCD28KO and wt CD8+ T cells were equally capable of killing allogeneic target cells in vivo and in vitro. Due to this sufficient anti-tumour activity of iCD28KO CD8+ T cells, they had a therapeutic effect in our GvL model and 25% of the mice survived until the end of the experiment (day 120) without any sign of the malignant disease. Similarly, CD28 deletion on all donor T cells induced long-term survival. This was not the case when all donor T cells were isolated from wt donor mice. In contrast to the beneficial outcome after CD28 deletion on all donor T cells or only CD8+ T cells, selective CD28 deletion on donor CD4+ Tconv cells completely abrogated the GvL effect due to insufficient CD4+ T cell help from iCD28KO CD4+ Tconv cells.
This study demonstrates that therapeutic inhibition of the co-stimulatory CD28 signal in either all donor T cells or only in CD8+ T cells might protect patients from aGvHD without increasing the risk of relapse of the underlying disease. Moreover, deletion of CD28 on donor Treg cells constitutes a mouse model of late-onset aGvHD which can be a useful tool in aGvHD research.
The aim of the present study was to design different dosage forms as carrier systems to deliver sorafenib to the lung of BXB-23 transgenic mice using different routes of administration. Three dosage forms were used one of them was an oil-in-water emulsion and the oral route was chosen for this experiment. The other delivery system was a liposome preparation for intratracheal instillation. In this case the oral route was considered as a control experiment. The last dosage form was PLGA microspheres. Before sorafenib administration it was important to develop a HPLC method to assess sorafenib absorption after its administration and to determine its concentrations in mouse serum. The HPLC method allowed sorafenib quantification in small volumes (30 µl) of mouse serum and tissues. The developed HPLC method was validated resulting in satisfactory selectivity, good linearity, good accuracy and precision over the concentration range examined. Sorafenib was successfully incorporated in a fat emulsion (o/w) using a traditional method resulting in a white homogenous emulsion and no particle aggregation was observed. Sorafenib exhibited antitumor activity on the lung adenoma in BXB-23 transgenic mice when administered orally (2 mg sorafenib per mouse) in the emulsion preparation. The determined effect was an approximately 29 % reduction in the tumor area of the adenoma foci and a proliferation reduction. In order to improve the pharmacological effects of sorafenib on the lung adenoma in BXB-23 mice, the targeting of sorafenib directly to the site of action (the lung) was an attractive concept. For this purpose the intratracheal route was used. Since sorafenib administration by instillation required incorporation of sorafenib in a dosage form suitable for its lipophilic nature, a liposome suspension was the second dosage form used. A lyophilization method was employed for sorafenib liposome preparation utilizing dilauroylphosphatidylcholine (DLPC) which is safe and tolerable for the lung. Incorporation of sorafenib in the liposomes did not influence the particle size and its distribution. The sorafenib liposomes showed high encapsulation efficiency, good stability at 4 °C for one month and satisfactory in vitro release properties and inhibited Raf-1 mediated activation of ERK in cell culture assay. In a pharmacokinetic experiment sorafenib loaded liposomes were instilled directly into the lung. The results revealed that a significant level of sorafenib was achieved in the lung tissues after 2 hours and then reduced after 48 h and remained nearly constant for one week. On the other hand, only traces of sorafenib were found in the mice serum up to 48 h. Subsequently, the pharmacological activity of sorafenib (1 mg per mouse) was studied when delivered in a liposomal suspension intratracheally to treat the lung adenoma of BXB-23 mice. The data of this experiment demonstrated that sorafenib intratracheal instillation resulted in a reduction of tumor area of adenoma foci (67 %) and an elevation of the percent of apoptotic cells. In contrast, prolongation of the treatment period did not further enhance sorafenib activity on the lung adenoma. This previous finding suggested a development of multidrug resistance (MDR) by the adenoma foci cells against sorafenib instillation, which was examined by immunohistochemistry staining. The percent of MDR positive cells was higher after two and three weeks sorafenib liposome instillation treatment than that after one week treatment. The last dosage form used for sorafenib was microspheres, which were prepared by emulsion-diffusion-evaporation method using biodegradable PLGA 50:50 resulting in a white lyophilized powder. The system was characterized physicochemically and revealed a good microspheres yield, high encapsulation efficiency, a homogenous particle size distribution and slow in vitro release of sorafenib. The other strategy studied in the present research project was gene delivery to target the lung bearing tumor of BXB-23 mice using a non-viral vector (polyethylenimine). Polyethylenimine (PEI) was used to investigate its efficiency in transfecting lung bearing tumor of BXB-23 mice model and its ability to transfect the adenoma foci cells. LacZ, which encodes Beta-galactosidase was used in the present study as a reporter gene and was complexed with PEI before delivered intravenously. A high LacZ expression in the alveolar region with some expression in the adenoma foci was observed. On contrary, a low LacZ expression in the alveoli and in the adenoma foci was achieved after instillation of the same polyplex intratracheally.